| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Chapter Links... |
 NICE TA 539: Neuroendocrine tumours (metastatic, unresectable, progressive) - 177 Lu-dotatate |
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
Aflibercept (Zaltrap®)
|
Formulary
|
Vials: 100mg/4ml, 40mg/1ml
|
NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration
NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
NICE TA 346: Aflibercept for treating diabetic macular oedema
NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
NICE TA 486: Aflibercept for treating choroidal neovascularisation
|
Atezolizumab
|
Formulary
|
Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed
Also available through patient access scheme for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
|
NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA 638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA 639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA 666:Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
|
Avelumab  (Bavencio ®)
|
Formulary
|
20mg/ml concentrate for infusion.
|
NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma
NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Axicabtagene ciloleucel
|
Formulary
|
|
NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies
|
Axitinib
|
Formulary
|
Film coated tablets: 1mg, 3mg, 5mg and 7mg
|
NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
|
Bosutinib
|
Formulary
|
Film coated tablets: 100mg, 500mg
|
NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
|
Carfilzomib (Kyrolis®)
|
Formulary
|
Vial: powder for infusion 10 mg, 30 mg and 60 mg
|
NICE TA 657: Carfilzomib for previously treated multiple myeloma
|
Ceritinib
|
Formulary
|
Capsule: 150mg
|
NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib (Tafinlar®)
|
Formulary
|
Capsules: 50mg and 75mg
Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE
|
NICE TA 321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Daratumumab (Darzalex ®)
|
Formulary
|
20mg/ml concentrate for infusion
|
NICE TA 510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
|
Encorafenib (Braftovi®)
|
Formulary
|
Capsules: 50 mg and 75 mg
|
NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA 668:Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
|
Entrectinib
|
Formulary
|
Capsules: 100mg and 200mg
|
NICE TA 643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA 644: Entrectinib for treating NTRK fusion-positive solid tumours
|
Eribulin (Halaven®)
|
Formulary
|
Vial: 0.88mg/2ml
Vial: 1.32mg/3ml
|
NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Gemtuzumab ozogamicin (Mylotarg®)
|
Formulary
|
Approved for untreated acute myeloid leukaemia in line with NICE
|
NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
|
Gilteritinib (as fumarate)
|
Formulary
|
Tablets: 40mg
|
NICE TA 642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Ibrutinib (Imbruvica®)
|
Formulary
|
Capsules: 140mg
|
NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Idelalisib
|
Formulary
|
Film coated tablets: 100mg, 150mg
|
NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
|
Inotuzumab ozogamicin (Besponsa®)
|
Formulary
|
Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE
|
NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Ixazomib (Ninlaro®)
|
Formulary
|
Capsules: 4mg
|
NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
|
Lenvatinib (Lenvima®)
|
Formulary
|
Capsules: 4mg and 10mg
|
NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA 551: Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma
|
Midostaurin (Rydapt ®)
|
Formulary
|
25mg capsules
|
NICE TA 522 Midostaurin for untreated acute myeloid leukaemia
|
Niraparib (Zejula®)
|
Formulary
|
Niraparib tosylate monohydrate 100mg capsules
|
NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer
|
Olaparib
|
Formulary
|
Capsules: 50mg
- Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed
- approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in line with NICE
|
NICE TA 598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA 620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
|
Olaratumab
|
Formulary
|
Concentrate for solution for infusion: 10 mg/mL
|
|
|
Osimertinib
|
Formulary
|
Tablet: 40mg and 80mg
|
NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
NICE TA 654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Pablociclib (Ibrance®)
|
Formulary
|
Recommended for use according to NICE criteria
|
NICE TA 619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Panobinostat (Farydak®)
|
Formulary
|
Hard capsules: 10mg, 15mg, 20mg
|
NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pembrolizumab (Keytruda®)
|
Formulary
|
Concentrate for infusion: 100 mg/4 mL
See below for NICE approved indications
|
NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA 522 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer where cisplatin is unsuitable
NICE TA 531: Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer
NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA 600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA 661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
|
Polatuzumab vedotin
|
Formulary
|
Vial: 30mg and 150mg, powder for concentrate for solution for infusion.
|
NICE TA 649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Ponatinib (Iclusig®)
|
Formulary
|
Tablets: 15mg, 45mg
|
NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Radium-223 dichloride
|
Formulary
|
|
NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
|
Rucaparib
|
Formulary
|
Film coated tablets: 200mg, 250mg, 300mg
|
NICE TA 611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
|
Ruxolitinib
|
Formulary
|
Tablets: 5mg, 15mg, 20mg
|
NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Talimogene laherparepvec (Imlygic®)
|
Formulary
|
Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml
-approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy
|
NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
|
Tisagenlecleucel (Kymriah®)
|
Formulary
|
Indicated for treating 'paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse as per NICE
NICE has recommended tisagenlecleucel for use within the Cancer Drugs Fund for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies.
|
NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
|
Tivozanib (Fotivda® )
|
Formulary
|
Capsules: 890 mg and 1340 mg
|
NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
|
Trametinib (Mekinist®)
|
Formulary
|
Film coated tablets: 500microgram, 2mg
|
NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
|
| 08.01.05 |
Amsacrine |
|
|
Amsacrine
|
Formulary
|
Injection: 75mg in 15ml
|
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
Arsenic Trioxide
|
Formulary
|
Ampoule: 10mg in 10ml
-NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL)
NICE TA for acute promyelocytic leukaemia
|
NICE TA 526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
| 08.01.05 |
Bevacizumab |
|
|
Bevacizumab (Avastin®)
|
Formulary
|
Vial: 100mg/4ml
Syringe: 5mg/0.2ml
Solution for infusion: 25mg/1ml
*Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable
|
NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
NICE TA 212: Colorectal cancer (metastatic) - bevacizumab
NICE TA 214: Breast Cancer with taxane
NICE TA 242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA 263: Breast cancer with capecitabine
NICE TA 284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA 285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
|
| 08.01.05 |
Bexarotene |
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib
|
Formulary
|
Injection: 3.5mg
|
NICE TA 129: Multiple myeloma - bortezomib
NICE TA 228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
NICE TA 311: Multiple myeloma - bortezomib (induction therapy
NICE TA 370: Bortezomib for previously untreated mantle cell lymphoma
|
| 08.01.05 |
Brentuximab vedotin |
|
|
Brentuximab vedotin (Adcetris®)
|
Formulary
|
Vial: 50mg
|
NICE TA 524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA 577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA 641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab
|
Formulary
|
Vials for IV infusion: 100mg in 20ml & 500mg in 100ml
|
NICE TA 118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
NICE TA 242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA 323 Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA 473: Head and neck cancer (squamous cell carcinoma) - cetuximab
|
| 08.01.05 |
Crisantaspase |
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
|
Formulary
|
Injection: 500mg
|
|
|
Streptozocin
|
Formulary
|
 unlicensed Injection: 1g (only available on a named patient basis)
|
|
|
Temozolomide
|
Formulary
|
Capsules: 5mg, 20mg, 100mg, 250mg
|
NICE TA 23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
NICE TA 121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
|
| 08.01.05 |
Erlotinib |
|
|
Erlotinib (Tarceva® )
|
Formulary
|
Tablets: 25mg, 100mg & 150mg
|
NICE TA 227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
NICE TA 258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
|
Formulary
|
Capsules: 500mg
unlicensed Suspension: 500mg in 5ml
|
|
|
| 08.01.05 |
Imatinab |
|
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab
|
Formulary
|
Vial for preparing IV infusion: 50mg
|
NICE TA 268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA 319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
|
| 08.01.05 |
Mitotane |
|
|
Mitotane
|
Formulary
|
Tablets: 500mg
|
|
|
| 08.01.05 |
Panitumumab |
|
|
| 08.01.05 |
Pentostatin |
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
|
Formulary
|
Injections: 50mg in 5ml, 450mg in 45ml
|
|
|
Cisplatin
|
Formulary
|
Injection: 50mg
|
|
|
Oxaliplatin
|
Formulary
|
Injections: 50mg, 100mg
|
NICE TA 100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
|
| 08.01.05 |
Porfimer sodium and temoporfin |
|
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
|
Formulary
|
Capsules: 50mg
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
|
Formulary
|
Film coated tablets: 20mg, 30mg, 40mg, 50mg
|
NICE TA 310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
|
Alectinib (Alecensa®)
|
Formulary
|
150mg capsules
|
NICE TA 536: Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
|
Brigatinib (Alunbrig®)
|
Formulary
|
Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE
|
NICE TA 570: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Cabozantinib
|
Formulary
|
Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy
|
NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib
|
Formulary
|
Capsules: 200mg, 250mg
|
NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Dacomitinib (Vizimpro®)
|
Formulary
|
Dacomitinib is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides it according to the commercial arrangement.
|
NICE TA 595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Dasatinib
|
Formulary
|
Tablets: 20mg, 50mg
|
NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Everolimus (Votubia®)
|
Formulary
|
Capsules: 2.5mg, 5mg, 10mg
-Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
-approved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy
Tablets: 5mg and 10mg
- Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
- Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
- Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
-Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE
|
NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Gefitinib (Iressa®)
|
Formulary
|
Tablets: 250mg
|
NICE TA 192: Lung cancer (non-small-cell, first line) - gefitinib
NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Imatinib
|
Formulary
|
Capsules: 100mg & 400mg
|
NICE TA 70: Leukaemia (chronic myeloid) - imatinib
NICE TA 86: Gastro-intestinal stromal tumours (GIST) - imatinib
NICE TA 209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
NICE TA 326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Larotrectinib
|
Formulary
|
Oral solution: 20mg/mL
Recommended for use according to NICE criteria (TA630)
|
NICE TA 630: Larotrectinib for treating NTRK fusion-positive solid tumours
|
Lorlatinib
|
Formulary
|
Tablets: 25mg, 100mg
Recommended for use according to NICE criteria (TA628)
|
NICE TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
|
Nilotinib
|
Formulary
|
Capsules: 150mg, 200mg
|
NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nintedanib (Vargatef®)
|
Formulary
|
Soft capsules: 100mg, 150mg
|
NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
|
Pazopanib
|
Formulary
|
Tablets: 200mg, 400mg
|
NICE TA 215: Renal cell carcinoma (first line metastatic) - pazopanib
|
Regorafenib (Stivarga® )
|
Formulary
|
Tablets: 40mg
|
NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Sorafenib
|
Formulary
|
Tablets: 200mg
|
NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma
|
Sunitinib
|
Formulary
|
Capsules: 50mg 100mg, 400mg
|
NICE TA 169: Renal cell carcinoma - sunitinib
NICE TA 178: Renal cell carcinoma
NICE TA 179: Gastrointestinal stromal tumours - sunitinib
|
Trifluridine and tipiracil
|
Formulary
|
Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy
|
NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
|
Vemurafenib
|
Formulary
|
Tablets: 240mg
|
NICE TA 269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Venetoclax (Venclyxto®)
|
Formulary
|
Tablets: 10 mg, 50 mg & 100 mg
|
NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA 663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
|
| 08.01.05 |
Taxanes |
|
|
Abraxane® (Paclitaxel)
|
Formulary
|
Powder for suspension for infusion: 5mg - restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.
|
NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
Cabazitaxel
|
Formulary
|
Concentrate for IV infusion: 40mg/1ml
|
NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel
|
Formulary
|
Injections: 20mg, 80mg
|
NICE TA 101: Prostate cancer (hormone-refractory) - docetaxel
|
Paclitaxel
|
Formulary
|
Concentrate for preparing IV infusion: 30mg in 5ml, 100mg in 16.7ml and 150mg in 25ml
|
NICE NG 101: Early and locally advanced breast cancer: diagnosis and management
NICE TA 55: Ovarian cancer - paclitaxel (review)
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan
|
Formulary
|
Injection: 40mg in 2ml & 100mg in 5ml
|
|
|
Topotecan
|
Formulary
|
Capsules: 0.25mg, 1mg capsules
Vials: 1mg, 4mg
|
NICE TA 183: Cervical cancer (recurrent) - topotecan
NICE TA 184: Lung cancer (small-cell) - topotecan
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin (Yondelis®)
|
Formulary
|
Injection: 250microgram
|
NICE TA 185: Soft tissue sarcoma - trabectedin
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trastuzumab |
|
|
Pertuzumab (Perjeta®)
|
Formulary
|
Vial: 420mg
|
NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA 569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Trastuzumab (Herceptin®)
|
Formulary
|
Vial for preparing IV infusion: 150mg
Injection: 600mg s/c injection
|
NICE TA 101: Early and locally advanced breast cancer: diagnosis and management
NICE TA 208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA 257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
NICE TA 34: Breast cancer - trastuzumab
|
Trastuzumab emtansine (Kadcyla®)
|
Formulary
|
|
NICE TA 235: Osteosarcoma - mifamurtide
NICE TA 632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
|
| 08.01.05 |
Tretinoin |
|
|
Tretinoin
|
Formulary
|
Capsules: 10mg
|
|
|
| 08.01.05 |
Vismodegib |
|
|
| .... |
| Non Formulary Items |
Bexarotene (Targretin®)
|
Non Formulary
|
|
|
|
Crisantaspase (Erwinase®)
|
Non Formulary
|
|
|
|
Ixazomib (Ninlaro®)
|
Non Formulary
|
|
|
|
Necitumumab
|
Non Formulary
|
|
|
|
Panitumumab (Vectibix®)
|
Non Formulary
|
|
|
|
Pentostatin (Nipent®)
|
Non Formulary
|
|
|
|
Porfimer Sodium (Photofrin ®)
|
Non Formulary
|
|
|
|
Sonidegib (Odomzo®)
|
Non Formulary
|
|
|
|
Temoporfin (Foscan®)
|
Non Formulary
|
|
|
|
Vandetanib (Caprelsa®)
|
Non Formulary
|
|
|
|
Vismodegib (Erivedge®)
|
Non Formulary
|
|
|
|
Vosaroxin (Qinprezo)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist.
These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.
|
|
These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug.
Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.
|
|
Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. |
|
These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care.
N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN. |
|
|
|
